MainStreet Investment Advisors LLC Purchases 600 Shares of Charles River Laboratories International, Inc. $CRL

MainStreet Investment Advisors LLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 24.3% in the second quarter, HoldingsChannel.com reports. The fund owned 3,065 shares of the medical research company’s stock after buying an additional 600 shares during the period. MainStreet Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $465,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. GW&K Investment Management LLC lifted its stake in Charles River Laboratories International by 41.1% during the first quarter. GW&K Investment Management LLC now owns 88,410 shares of the medical research company’s stock worth $13,307,000 after purchasing an additional 25,744 shares during the last quarter. Balefire LLC increased its stake in shares of Charles River Laboratories International by 39.4% in the 2nd quarter. Balefire LLC now owns 13,494 shares of the medical research company’s stock valued at $2,047,000 after purchasing an additional 3,815 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Charles River Laboratories International by 47.1% during the 2nd quarter. Fifth Third Bancorp now owns 12,871 shares of the medical research company’s stock worth $1,953,000 after buying an additional 4,124 shares in the last quarter. HB Wealth Management LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth $306,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Charles River Laboratories International by 29.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after buying an additional 516,521 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CRL. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Barclays lifted their price target on shares of Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. upped their price objective on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. Finally, Argus set a $200.00 target price on shares of Charles River Laboratories International in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Stock Up 0.1%

Shares of NYSE CRL opened at $162.83 on Wednesday. The company has a 50 day simple moving average of $168.87 and a 200 day simple moving average of $158.21. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $203.01. The firm has a market cap of $8.01 billion, a PE ratio of -122.43, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same period in the previous year, the firm posted $2.59 EPS. The company’s revenue for the quarter was down .5% compared to the same quarter last year. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).